



## Conference on ‘Nutrition at key stages of the lifecycle’ Symposium four: Nutrition for the prevention of CVD across the life span

### Long chain n-3 polyunsaturated fatty acid intake across the life span for cardiovascular disease prevention in women

Wendy Louise Hall 

*Department of Nutritional Sciences, School of Life Course and Population Sciences, Faculty of Life Sciences and Medicine,  
King's College London, London, UK*

Cardiovascular diseases (CVDs) are a major health concern for women. Historically there has been a misconception that men are at greater risk because CVD tends to occur earlier in life compared to women. Clinical guidelines for prevention of heart disease are currently the same for both sexes, but accumulating evidence demonstrates that risk profiles diverge. In fact, several CVD risk factors confer an even greater risk in women relative to men, including high blood pressure, obesity, diabetes and raised triglycerides. Furthermore, many female-specific CVD risk factors exist, including early menarche, pregnancy complications, polycystic ovary syndrome, reproductive hormonal treatments and menopause. Little is known about how diet interacts with CVD risk factors at various stages of a woman's life. Long chain (LC) n-3 polyunsaturated fatty acid (PUFA) intakes are a key dietary factor that may impact risk of CVD throughout the life course differentially in men and women. Oestrogen enhances conversion of the plant n-3 PUFA, alpha-linolenic acid, to LCn-3 PUFA. Increasing the frequency of oily fish consumption or LCn-3 PUFA supplementation may be important for reducing coronary risk during the menopausal transition, during which time oestrogen levels decline and the increase in CVD risk factors is accelerated. Women are under-represented in the evidence base for CVD prevention following LC n-3 PUFA supplementation. Therefore it is not clear whether there are sex differences in response to treatment. Furthermore, there is a lack of evidence on optimal intakes of LC n-3 PUFA across the lifespan for CVD prevention in women.

**Key words:** n-3 PUFA: Women's health: Life course: Cardiovascular disease: Diet

Lifestyle strategies to improve population cardiometabolic health remain a high priority as cardiovascular disease (CVD) continues to be a leading global health challenge<sup>(1)</sup>. Clinical guidelines for prevention of heart disease are currently the same for men and women<sup>(2)</sup>, despite evidence suggesting that there are sex differences in risk profiles and divergent physiological changes across the lifespan that may influence the impact of generic recommendations<sup>(3)</sup>. This is particularly relevant to the

roles that dietary long-chain n-3 polyunsaturated fatty acids (LCn-3 PUFA) play in influencing risk of CVD, due to interactions with reproductive hormones and female-specific CVD risk factors, to be discussed later. This review critically examines the evolving body of knowledge concerning the impact of LCn-3 PUFA intake on CVD prevention in women, traversing the diverse stages of their lives from adolescence to postmenopausal years. The aim of this review is to summarise our understanding of the

cardiovascular health impact of LCn-3 PUFA intakes across the female life course and to recommend priority areas for future research.

### The impact of CVD on women

Research on the prevention and management of CVD in women has been comparatively neglected by the research community. However, awareness is increasing that CVD research does not predominantly belong in the domain of men's health<sup>(4)</sup>. In the global female population, CVD is the primary cause of death, accounting for 35% of mortality<sup>(5)</sup>. Although CVD deaths in both sexes have been declining in countries with a high socio-demographic index (SDI), CVD remains responsible for a high proportion of deaths (34% in women, 30% in men across all high SDI countries). Furthermore, the proportion of deaths from CVD is increasing in low and middle SDI countries<sup>(5)</sup>.

Worryingly, the prevalence of cardiovascular morbidity in younger women is increasing year on year. For example, data from a UK representative primary care database showed that whilst incidences and prevalences of diagnosed coronary heart disease (CHD) and angina were decreasing in women aged 16–50 years, there was an upward trend in myocardial infarction (MI) and revascularisation procedures from 1998 to 2017<sup>(6)</sup>. A Lancet report on women and CVD (2021) was commissioned on the basis that 'CVD in women remains understudied, under-recognised, underdiagnosed and undertreated'<sup>(7)</sup>, with the article culminating in key recommendations to reduce the global burden by 2030.

### Differential impacts of cardiovascular risk factors in women

Many of the traditional modifiable risk factors for heart disease have been reported to confer a higher relative risk in women compared to men. Although these data are limited by the lack of representation of populations from non-European regions, they indicate that sex-specific cut-offs for risk factors in addition to waist and HDL cholesterol in clinical guidelines may facilitate better identification of women at increased risk of CVD. Obesity is one of these risk factors that confers a greater risk of CVD in women than men. For example, the age-adjusted relative risk of CVD associated with obesity was 1.64 (1.37–1.98) in women compared with 1.46 (1.20–1.77) in men in the Framingham heart study prospective cohort<sup>(8)</sup> and the hazard ratio for cardiovascular mortality in a German prospective cohort was 1.70 (1.27–2.28) in the highest v. lowest quartile for waist circumference for women compared with 1.28 (1.04–1.57) in men<sup>(9)</sup>. A higher waist-hip ratio increased risk of a CVD event across all BMI categories in women but not men in a Swedish cohort<sup>(10)</sup>, which is particularly pertinent to risk in women at midlife and beyond since the prevalence of central obesity is higher in postmenopausal women<sup>(11)</sup>. In addition, the greater relative risk of CVD in women with

obesity is compounded by the fact that a significant proportion of women experience gestational weight gain and post-partum weight retention<sup>(12)</sup>.

Hypertension increases CVD risk more in women than men, accounting for 36% of risk of MI among women v. 20% of risk among men in the INTERHEART case-control study<sup>(13)</sup>. In a study of combined prospective cohorts where blood pressure measurement was standardised, CVD risk increased at a lower blood pressure threshold in women compared to men<sup>(14)</sup>, leading to suggestions that sex-specific ranges for normal and raised blood pressure are needed for assessing CVD risk. In addition, women experience an accelerated age-related increase in blood pressure in later life<sup>(15)</sup>. Fasting blood triglycerides are more strongly independently associated with risk of CHD in women compared with men<sup>(16)</sup>. Non-fasting triglycerides are superior to fasting triglycerides in predicting risk of CHD and are also associated with a greater increase in risk of myocardial infarction in women compared to men, according to data from a Norwegian cohort<sup>(17)</sup>.

Convincing evidence shows that the relative risk of CVD in people living with diabetes is greater in women than men<sup>(18–21)</sup>. These sex differences may be linked to the fact that women carry excess adiposity for a longer duration before the pathology of insulin resistance and impaired insulin secretion tips into overt type 2 diabetes, which renders them exposed to other cardiovascular risk factors for a longer period<sup>(22)</sup>. In addition, a lack of understanding of sex-specific responses to therapies and disparities in clinical management are likely to play an important role<sup>(23)</sup>. Other intertwining risk factors such as demands of domestic/family roles traditionally shouldered by women result in more limited opportunities for physical exercise. Lower physical activity levels may then interact with other risk factors such as hypertension and diabetes to amplify the heightened vascular risk associated with being female with these cardiovascular risk factors<sup>(24)</sup>. Finally, depression is associated with a greater risk of CVD in women compared with men<sup>(25)</sup>, and since women have a greater likelihood of developing depression, poor mental health is another important CVD risk factor that impacts women disproportionately.

### Longer chain n-3 PUFA: sex-specific dietary recommendations and intakes

Dietary longer chain n-3 PUFA originate in marine microalgae that can carry out de novo synthesis of highly unsaturated fatty acids (SFA), including EPA (EPA; 20 : 5n-3), docosapentaenoic acid (DPA; 22 : 5n-3) and DHA (DHA; 22 : 6n-3). These LCn-3 PUFA become concentrated at each stage in the food chain, making fish a rich source of EPA, DPA and DHA. The other major n-3 fatty acid in the diet, the 18-carbon chain essential fatty acid,  $\alpha$ -linolenic acid (ALA; 18 : 3n-3), is derived from plant foods (particularly vegetable oils, walnuts and seeds). ALA can be converted in small proportions to EPA, then DPA, and to a very limited extent to DHA in the body<sup>(26)</sup>.

An abundance of evidence points to the beneficial effects of LCn-3 PUFA on the pathological pathways that

underlie CVD. The mechanisms mediating cardioprotective effects include those related to their preferential incorporation into cellular membranes, which may reduce risk of sudden cardiac death by lowering heart rate<sup>(27)</sup>, improving cardiac autonomic function<sup>(28,29)</sup> and modulating ion channel function and cell signalling pathways<sup>(30)</sup>. Other pathways involved their direct effects on vasodilators in the vasculature<sup>(31)</sup>, inhibition of inflammatory molecules and conversion to less proinflammatory eicosanoids and pro-resolving mediators that dampen and resolve inflammation<sup>(32)</sup>, also by inhibiting platelet aggregation at higher doses<sup>(33)</sup>, and by increasing lipoprotein lipase expression and activity<sup>(34)</sup>, lipid oxidation<sup>(35)</sup> and decreasing de novo lipogenesis via modulation of liver transcription factors that regulate expression of lipogenic enzymes<sup>(36,37)</sup>, leading to a reduction in blood triglycerides<sup>(38)</sup>.

Oily fish is the main source of dietary LC n-3 PUFA (on average 2.8 g per 140 g portion)<sup>(39)</sup>, with small amounts derived from non-oily fish (0.4 g per portion)<sup>(39)</sup>, eggs (0.1–0.2 g per egg)<sup>(40,41)</sup> and grass-fed beef/lamb (0.03–0.04 g per 100g)<sup>(40,42)</sup>. Clearly, other nutritional benefits of fish exist apart from fatty acid composition: they are a good source of high-quality protein and micronutrients that are in limited supply elsewhere in the diet, including vitamin D, selenium and iodine. It is also important to consider that the total effects of fish consumption on health may be modified by other potentially harmful factors such as less favourable cooking methods<sup>(43)</sup> and marine pollutants<sup>(39)</sup>.

Recommendations in the UK, originating from the 2004 SACN report<sup>(39)</sup>, are to consume at least 2 portions of fish/wk (at least 1 of which should be oily). Female-specific recommendations were included, for example, 'Pregnant women, women intending to become pregnant, and under-16's should avoid shark, marlin and swordfish, but can eat up to 4 medium-sized tins tuna or 2 tuna steaks per week' when considering risks of methylmercury contamination, and 'women past reproductive age, boys and men should consume 1–4 portions oily fish a week – women of reproductive age and girls 1–2 portions oily fish a week' when considering risks of dioxins<sup>(39)</sup>. However, representative data from the National Diet and Nutrition Survey Y1-11 indicates that the UK population fall far short of meeting recommendations. Over the whole survey period from 2008 to 2019 (*n* 7207 males and *n* 8448 females) only 11.7% of females and 10.7% of males of all ages met government recommendations to consume 1 portion of oily fish per week (estimated as >20 g/d from 4 d food diaries). There were no discernable changes in oily fish intakes over time in either sex (own analysis, National Diet & Nutrition Survey (NDNS) Y1-11)<sup>(44)</sup>. These data suggest that most of the UK population are at risk of suboptimal tissue EPA and DHA status. Further analysis by age group reveals that 87.4% and 87.9% of females and males, respectively, under the age of 18 years, reported consuming no oily fish (Table 1)<sup>(44)</sup>. Only 4.2% of females and 4.7% of males under-eighteens reported that they consumed the recommended amount. The proportion of women consuming oily fish was higher with age, with up to one-quarter of 66–80 year old females

meeting guidelines, and a further 10.9% consuming some oily fish (Table 1)<sup>(44)</sup>. Concerningly, more than three-quarters of women may not be consuming any oily fish during child-bearing years (Table 1).

### *n-3 PUFA status through the female life course*

Using red blood cell (RBC) membrane profiles as a proxy for tissue status, it can be determined that there are sex-specific variations in tissue omega-3 fatty acid status across the lifecourse<sup>(45)</sup>. Data from 160 000 blood samples sent to a commercial clinical laboratory showed that the proportion of RBC lipids as ALA was higher in women than men across all ages whereas the proportion as EPA was lower in women until their 50's<sup>(45)</sup>. The proportion of RBC lipids as DHA increased with age in both sexes, but was higher in female adolescents and women in their twenties than men of equivalent age<sup>(45)</sup>. These sex differences in tissue pools may reflect differences in conversion of EPA to DHA in pre-menopausal women. The conversion of ALA to EPA and then to DHA is known to be enhanced by oestrogen, as indicated by stable isotope-based research showing that the rate of conversion of labelled ALA to EPA was 8% in men and 21% in women (whose average age was 28 years), and then further conversion to DHA was <1% in men and 9% in women<sup>(46,47)</sup>. Women on oral oestrogenic contraceptives have higher circulating DHA concentrations<sup>(48–50)</sup>, although this might not be true for all ethnic groups<sup>(51)</sup>. Postmenopausal women taking hormone replacement therapy (HRT) have higher erythrocyte DHA compared with those not on HRT<sup>(52)</sup>. Research in animal models has shown that oestrogen enhances PPAR $\alpha$  activity leading to increased expression of the fatty acid desaturase 2 (FADS2) enzyme which desaturates ALA and DPA, and elongases, which increase the chain length along the conversion pathway<sup>(53)</sup>.

After the menopause, oestrogen levels rapidly decline leading to documented increases in CVD risk factors including raised blood pressure<sup>(54,55)</sup> and lipids<sup>(56,57)</sup>, inflammation<sup>(57,58)</sup>, central adiposity<sup>(58,59)</sup>, impaired glucose homeostasis<sup>(58)</sup> and vascular dysfunction<sup>(60)</sup>. Arguably, an additional CVD risk factor associated with menopause is very likely to be reduced conversion of ALA to EPA and DHA, potentially leading to increased requirements for dietary EPA and DHA after menopause. Greater dietary LCn-3 PUFA requirements after the menopause may mean that postmenopausal women respond to supplementation more favourably than men, evidence for which will be discussed in the next section.

### **Evidence supporting the role of LC-n-3 PUFA supplementation for prevention of CVD in women**

Decades of research points to the beneficial cardiovascular health effects of consuming n-3 fatty acids<sup>(61)</sup>. Epidemiological evidence has been pivotal in the development of dietary guidelines for fish consumption for prevention of CHD<sup>(39)</sup>. Few epidemiological studies have focused on women, but a notable example was the Nurses'

**Table 1.** Percentages of females and males meeting recommendations for consuming oily fish (1 portion per week, estimated at >20 g/d) by age category using 4-day food diary data from the National Diet and Nutrition Survey Rolling Programme Years 1–11 for 15 655 individuals

|                  |                  | Percentage of individuals in categories of oily fish consumption by age category |        |        |        |        |        |        |
|------------------|------------------|----------------------------------------------------------------------------------|--------|--------|--------|--------|--------|--------|
| Age category (y) |                  | ≤18                                                                              | 19–34  | 35–49  | 50–65  | 66–80  | ≥81    | Total  |
| Female           | Total <i>n</i>   | 7656                                                                             | 1652   | 2456   | 2028   | 1476   | 387    | 15 655 |
|                  | <i>n</i>         | 3749                                                                             | 1025   | 1452   | 1140   | 844    | 238    | 8448   |
|                  | ≤0.10 g/d        | 87.4 %                                                                           | 80.7 % | 78.2 % | 65.8 % | 62.9 % | 66.8 % | 79.1 % |
|                  | 0.11 – 20.00 g/d | 8.4 %                                                                            | 10.0 % | 8.5 %  | 11.1 % | 10.9 % | 9.2 %  | 9.3 %  |
|                  | >20.00 g/d       | 4.2 %                                                                            | 9.3 %  | 13.3 % | 23.1 % | 26.2 % | 23.9 % | 11.7 % |
| Male             | <i>n</i>         | 3907                                                                             | 627    | 1004   | 888    | 632    | 149    | 7207   |
|                  | ≤0.10 g/d        | 87.9 %                                                                           | 83.6 % | 75.8 % | 75.2 % | 63.0 % | 64.4 % | 81.6 % |
|                  | 0.11 – 20.00 g/d | 7.4 %                                                                            | 5.3 %  | 9.3 %  | 7.9 %  | 9.2 %  | 7.4 %  | 7.7 %  |
|                  | >20.00 g/d       | 4.7 %                                                                            | 11.2 % | 14.9 % | 16.9 % | 27.8 % | 28.2 % | 10.7 % |

Health Study which reported that women consuming fish 5 or more times a week had a 32 % reduced risk of all-cause mortality and 31 % reduced risk of total CHD compared to those consuming less than once a month<sup>(62)</sup>. In a meta-analysis study that showed a dose-response relationship between fish consumption and CHD incidence<sup>(63)</sup>, a sub-analysis was conducted on 8 of the studies where analysis by sex was possible; this showed that there was a 15 % lower relative risk of CHD incidence in females, but no associations in males for CHD incidence, suggesting that the relationship between fish consumption and CHD incidence may be stronger in women<sup>(63)</sup>.

Limitations of using prospective cohort studies on fish consumption as evidence for the role of LC n-3 PUFA in disease risk include residual confounding from other elements of the diet that often co-exist with patterns of fish consumption (for example higher intakes of fish may mean lower intakes of red meat), as well as other factors. In addition, variability in n-3 PUFA or marine contaminant content cannot be taken into account, and it is impossible to isolate the contribution of n-3 PUFA from other oily fish-derived nutrient components such as iodine, selenium and vitamin D. Randomised controlled trials (RCTs) are needed to confirm causal effects of LCn-3 PUFA on CHD risk. Many of the RCTs that included CVD events or mortality as primary outcomes have tested pharmaceutical-grade fish oil or purified fatty acids as the intervention<sup>(64)</sup>. It is well-established that EPA/DHA supplements are particularly effective in tackling hypertriglyceridaemia<sup>(38,65)</sup>, which is associated with a greater risk of CHD in women compared to men<sup>(16)</sup>. FINGEN was a key RCT powered to investigate sex differences; it was reported that 0.7 g/d EPA + DHA reduced triglycerides to a similar extent in men and women, but that the higher dose of 1.8 g/d (roughly equivalent to 4 portions oily fish per week) was more effective in men<sup>(66)</sup>. More evidence is needed from trials specifically designed to test whether there are female-specific age- or menopause-related changes in lipid responses to fish oil supplementation in order to support life course-targeted advice on fish oil supplementation.

Although many studies such as FINGEN reported effects of LC n-3 PUFA on fasting TAG<sup>(66,67)</sup>, in fact, non-fasting TAG are superior in predicting risk of CHD<sup>(17)</sup>.

We have recently reported that postmenopausal status is associated with higher postprandial triglyceride concentrations following high-fat meals in the predominantly female PREDICT 1 UK cohort (*n* 1002; pre-*n* 366, peri-*n* 55 and postmenopausal females *n* 206; adjusted for age, BMI, HRT and smoking status)<sup>(68)</sup>, although in analysis of a small age-matched cohort to separate age-related effects from oestrogen status, this was not replicated (pre-*n* 86 and postmenopausal *n* 64). However, this does not rule out an important role of oestrogen in the relationship between non-fasting TAG and risk of heart disease. Interestingly, postprandial lipaemia was lower in women on HRT compared with those not on HRT suggesting that oestrogen is likely to have an important role in postprandial lipid metabolism<sup>(68)</sup>. Unfortunately, most chronic fish oil interventions with postprandial lipaemia as an outcome are either in men and or not designed to report sex-specific responses so it is currently unclear whether menopausal status modifies the effects of fish oil on non-fasting triglyceride concentrations<sup>(69–74)</sup>.

The first large randomised controlled trials of LC n-3 PUFA and CHD outcomes started to emerge in the 1990's and 2000's showing promising reductions in secondary prevention of CHD<sup>(75–78)</sup>. However, by the 2010's, evidence was mounting that n-3 fatty acids were not effective in preventing CHD in either primary prevention (in populations without prior disease) or secondary prevention (in populations with existing disease) populations<sup>(79–84)</sup>, and there have been many theories on why these trials failed to replicate earlier results<sup>(85)</sup>. From 2012 until 2018, a number of meta-analyses concluded there was insufficient evidence for benefits of fish oil supplementation in the prevention of various outcomes including CVD/CHD deaths, cardiovascular events, sudden cardiac death, cardiac events/MI and stroke<sup>(86–89)</sup>, but the inclusion of two later trials in post-2018 meta-analyses resulted in modest but statistically significant pooled risk reductions of 8–10 % in risk for CHD death<sup>(64,90,91)</sup>, total CHD<sup>(90)</sup>, CVD death<sup>(64,90,91)</sup>, total CVD<sup>(90)</sup>, CHD events<sup>(64,91)</sup> and total MI<sup>(64,90,91)</sup>. The VITAL (0.85 g/d EPA + DHA ethyl esters)<sup>(92)</sup> and REDUCE-IT (4 g/d icosapent ethyl; 100 % EPA)<sup>(93)</sup> trials reported that LCn-3 PUFA supplementation significantly reduced risk of total MI by 28 % and 31 %, respectively, and risk of coronary revascularization (specifically percutaneous coronary intervention in the

VITAL study, not including coronary artery bypass grafting) by 22 % and 34 % respectively<sup>(92,93)</sup>, although the VITAL trial found no statistically significant effect on its primary endpoint, a composite of myocardial infarction, stroke or death from cardiovascular causes<sup>(92)</sup>.

In nearly all these RCTs, the proportion of women in the sample population was low (Table 2). Studies that showed no benefit ranged from 10–38 % of participants being female<sup>(79–84,94,95)</sup>, and in those that showed benefit the range was 15–69 %<sup>(75,77,92,93)</sup>. The only study that was designed and statistically powered to look at sex differences was the VITAL trial, which included healthy men above the age of 50 and healthy women above the age of 55 years<sup>(92)</sup>; no sex differences in risk reductions were shown across the whole sample, although presence or absence of significant interactions with potential modifiers of treatment by sex interactions such as ethnicity, background dietary intake of fish/tissue EPA and DHA status, or BMI were not presented. Based on this single trial, evidence suggests that men and postmenopausal women benefit similarly from EPA and DHA supplementation, at least in primary prevention populations where the prevalence of fish consumption was relatively high (median intake 1.5 servings/week), use of HRT was low (12 %), and the dose of EPA and DHA was equivalent to the amount that can be derived from consuming 2 portions of oily fish per week<sup>(92)</sup>. Further evidence is needed to determine whether HRT might improve responsiveness to LCn-3 PUFA supplementation in women, particularly among women who consume very little fish.

The REDUCE-IT trial, which reported a significant 25 % reduction in major adverse cardiovascular events including a 20 % reduction in cardiovascular death<sup>(93)</sup>, differed from other LCn-3 PUFA supplementation studies in several study design features. Firstly, like the 2007 JELIS trial<sup>(75)</sup>, the capsules contained EPA only, but as a purified EPA ethyl ester, and at a very high dose (4 g/d)<sup>(93)</sup>. All participants were hypertriglyceridaemic, statin-treated CVD patients or had diabetes plus another risk factor. The placebo control capsule contained 4 g/d pharmaceutical-grade mineral oil rather than a culinary oil, and there has been much debate on whether the mineral oil compromised the results by having unfavourable effects on inflammation<sup>(96,97)</sup>. Nevertheless, evidence from the REDUCE-IT trial was considered strong enough to form the basis of new medical guidelines in many countries<sup>(98)</sup>, which supported 4 g/d icosapent ethyl (pure EPA ethyl esters) treatment for lowering CV risk in patients with high blood TAG concentrations, with established atherosclerotic CVD or diabetes with risk factors, and being treated with statins. Considering the dynamic relationship between changes in oestrogen, CVD risk factors, and tissue LC n-3 PUFA status following menopause, it could be argued that there is strong justification for conducting more research on sex differences in the effectiveness of icosapent ethyl on health outcomes. However, for decades women have faced historical disparities in the management of CVD, with research and clinical practices often being disproportionately weighted towards male patients. This has resulted in underdiagnosis, misdiagnosis and suboptimal

treatment for women. Women are less likely to be prescribed lipid-lowering medication in primary care<sup>(99,100)</sup> or as part of secondary prevention treatment for CVD<sup>(101)</sup>, to undergo diagnostic procedures for atherosclerosis<sup>(101)</sup>, or to be referred to, or able to access, cardiac rehabilitation<sup>(102,103)</sup>; time will tell whether prescription and evaluation of high-dose EPA for CVD prevention will be equitable across sexes.

### *Causes of differential CVD risks throughout the female life course*

LCn-3 PUFA supplementation primary and secondary prevention studies tend to focus on populations at midlife and older due to statistical power constraints. However, the involvement of n-3 fatty acids in the maintenance of cardiovascular health is not confined to later life. Modifiable CVD risk factors, present from childhood and early adolescence onwards<sup>(104)</sup>, have consequences for atherogenesis and cardiovascular health throughout the whole life course. In fact, there are sex-specific factors at many stages of a woman's life that may interact with diet to impact the rate of CVD risk accrual (Fig. 1).


*Menstrual and ovarian abnormalities.* Menstrual abnormalities are associated with chronic inflammation and hormonal irregularities, and aspects of menstrual abnormalities such as irregular cycles<sup>(105,106)</sup>, pre-menstrual tension<sup>(107)</sup>, menorrhagia<sup>(108)</sup> and dysmenorrhoea<sup>(109)</sup> have been associated with increased risks of CHD or hypertension. Fish oil supplements may have some beneficial impact on the severity of these conditions but studies are small and heterogeneous so more evidence is needed<sup>(110,111)</sup>. Polycystic ovary syndrome (PCOS) is a hyperandrogenic endocrine disorder that begins during puberty and causes polycystic ovarian morphology, ovulation disorders, irregular periods, hirsutism and acne. Insulin resistance is present in 65–80 % of women with PCOS<sup>(112)</sup>, as well as a greater prevalence of CVD risk factors<sup>(113,114)</sup>. LCn-3 PUFA supplementation may be beneficial in reducing CVD risk factors in women with PCOS, but there is currently a lack of convincing interventional evidence to make recommendations<sup>(115)</sup>. The British Dietetic Association, however, recommends dietary omega-3 FA in women living with PCOS.

*Adverse pregnancy outcomes.* Many studies have shown that various pregnancy complications are associated with an increased risk of CHD<sup>(116,117)</sup>. The presence of underlying risk factors for CVD, such as a predisposition to high blood pressure or diabetes, combined with the physiological stress of carrying and growing a foetus, may result in adverse pregnancy outcomes. On top of this, enduring and surviving a pregnancy complication may cause long-term damage that may render the women more susceptible to developing CVD in later life. The relative risk of CHD events associated with pregnancy complications is estimated at 1.49 (1.38–1.60) for preterm delivery<sup>(118)</sup>, 2.50 (1.43–4.37) for pre-eclampsia<sup>(119)</sup> and 1.59 (1.30–1.94) for gestational diabetes<sup>(120)</sup>. Pregnancy complications have also been

**Table 2.** A selection of randomised controlled trials (where  $n > 500$  per randomised group) of LC n-3 PUFA supplementation in the primary and secondary prevention of CVD, showing dose of EPA + DHA, or EPA, the percentage of the sample population that was female, primary outcomes and any analysis by sex

| Trial                                         | Sample size                                    | % female | Supplement | Dose (g/d) | Primary/ secondary/ mixed prevention | Beneficial effects on CVD (Y/N) | Primary outcome                                                                                                                                        | Analysis by sex                                                                               |
|-----------------------------------------------|------------------------------------------------|----------|------------|------------|--------------------------------------|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| GISSI-Prevenzione, 1999 <sup>(77)</sup>       | 5666 intervention, 5658 control                | 15       | EPA + DHA  | 0.85       | Secondary                            | Y                               | Time to death or admission to hospital for CV reasons                                                                                                  | N                                                                                             |
| SU.FOL.OM3, 2010 <sup>(83)</sup>              | 1253 intervention, 1248 control                | 19       | EPA + DHA  | 0.6        | Secondary                            | N                               | Composite of MI, cerebral vascular ischaemic accident or CV deaths                                                                                     | N                                                                                             |
| Alpha Omega, 2010 <sup>(82)</sup>             | 1212 ALA + EPA/ DHA intervention, 1236 control | 22       | EPA + DHA  | 0.4        | Secondary                            | N                               | CVD events                                                                                                                                             | Y – 27 % ↓ in major cardiovascular events following ALA supplementation among women only (NS) |
| OMEGA, 2009 <sup>(84)</sup>                   | 1940 intervention, 1911 control                | 25       | EPA + DHA  | 0.84       | Secondary                            | N                               | Sudden cardiac death, cardiac arrest                                                                                                                   | N                                                                                             |
| OMEMI, 2021 <sup>(79)</sup>                   | 505 intervention, 509 control                  | 29       | EPA + DHA  | 1.59       | Secondary                            | N                               | No effect on composite primary outcome or other CVD outcomes                                                                                           | Y – no difference                                                                             |
| REDUCE-IT, 2019 <sup>(93)</sup>               | 4089 intervention, 4090 control                | 29       | EPA        | 4.0        | Mixed                                | Y                               | Composite of CV death, MI, stroke, coronary revascularisation and hospitalisation for unstable angina                                                  | Y – no difference                                                                             |
| GISSI-HF, 2008 <sup>(76)</sup>                | 3494 intervention, 3481 control                | 33       | EPA + DHA  | 0.87       | Secondary                            | Y                               | Time to death or admission to hospital for CV reasons                                                                                                  | N                                                                                             |
| ORIGIN, 2012 <sup>(81)</sup>                  | 6319 intervention, 6292 control                | 35       | EPA + DHA  | 0.84       | Primary                              | N                               | Composite of the 1st occurrence of CV death, nonfatal MI or nonfatal stroke                                                                            | N                                                                                             |
| STRENGTH, 2020 <sup>(94)</sup>                | 6539 intervention, 6539 control                | 35       | EPA + DHA  | 4.0        | Secondary                            | N                               | Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization and hospitalisation for unstable angina | Y – no difference                                                                             |
| ASCEND, 2018 <sup>(95)</sup>                  | 7740 intervention, 7740 control                | 37       | EPA + DHA  | 0.85       | Primary                              | N                               | Serious vascular events (first of MI, stroke, TIA or vascular death)                                                                                   | Y – no difference                                                                             |
| Risk & Prevention Study, 2013 <sup>(80)</sup> | 6244 intervention, 6269 control                | 38       | EPA + DHA  | 0.85       | Secondary                            | Y                               | Composite of time to death from CV causes or hospital admission for CV causes                                                                          | Y – 18 % ↓ death, nonfatal MI and nonfatal stroke in women                                    |
| VITAL, 2019 <sup>(92)</sup>                   | 12 933 intervention, 12 938 control            | 51       | EPA + DHA  | 0.85       | Primary                              | Y                               | Reduction in risk for total cancer and CVD events (a composite of MI, stroke and CV mortality) – no effect.<br>28 % ↓ total MI                         | Y – no difference                                                                             |
| AREDS2, 2014 <sup>(136)</sup>                 | 2147 intervention, 2056 control                | 57       | EPA + DHA  | 1.0        | Primary                              | N                               | Development of advanced age-related macular degeneration                                                                                               | N                                                                                             |
| JELIS, 2007 <sup>(75)</sup>                   | 9326 intervention, 9319 control                | 69       | EPA        | 1.8        | Mixed                                | Y                               | Major coronary events ↓ 19 %                                                                                                                           | Y – no difference                                                                             |

Abbreviations: EPA, eicosapentaenoic acid; DHA, DHA; MI, myocardial infarction; TIA, transient ischaemic attack.



**Fig. 1.** Female-specific cardiovascular risk factors through the life course.

associated with increased risk of hypertension, diabetes and dyslipidaemia in later life which may mediate the increased risk of CVD<sup>(117)</sup>.

Tissue LCn-3 PUFA metabolism could be a significant factor in the pathology of adverse pregnancy outcomes. Maternal and cord blood DPA and DHA concentrations in women with pre-eclampsia were 55–67% of control maternal and cord blood levels and similar patterns were observed in women with intrauterine growth restriction<sup>(121)</sup>. Maternal EPA was slightly higher in women with pre-eclampsia (~121%) than control maternal EPA concentrations<sup>(121)</sup>, suggesting that this may be at least in part attributable to reduced conversion of EPA to DHA. Further investigation revealed reduced subcutaneous (but not visceral) adipose tissue FADS1 and FADS2 gene expression and an absence of elongase expression in samples from women with pre-eclampsia, lending further support to the notion that this condition is linked to the disruption of EPA conversion to DHA<sup>(121)</sup>. However, it is unclear whether the disrupted EPA to DHA conversion is in the causal pathway for pre-eclampsia, or whether the pathology of pre-eclampsia and disruption to conversion enzymes both arise from a common origin.

Supplementation intervention trials could shed light on whether low conversion rates are causal in the pathology of pregnancy complications. A meta-analysis of RCTs concluded that supplementation may reduce risk of pre-eclampsia but it is uncertain, with a calculated overall relative risk that was not statistically significant (RR 0.84, 0.69–1.01; 20 trials, *n* 8306), plus the evidence was rated low quality<sup>(122)</sup>. However, the evidence strongly suggests that LCn-3 PUFA supplementation during pregnancy reduces risk of preterm birth by 11% (RR 0.89, (0.81–0.97); 26 trials, *n* 10 304; high-quality evidence), with an even stronger reduced risk of early (<34 weeks) preterm birth (RR 0.58, (0.44–0.77) trials, *n* 5204; high-quality evidence); indeed there was a greater incidence of very long pregnancies (>42 weeks) following supplementation<sup>(122)</sup>.

**Menopause.** The decline in oestrogen production has significant implications for body tissue LCn-3 PUFA status, as discussed at an earlier point in this review. However, simply replacing oestrogen through hormone replacement therapy may not be suitable for all postmenopausal women. Oral oestrogen plus progestin therapy was found to increase CHD risk during the first year of treatment in women in late menopause in the Heart and Estrogen/progestin Replacement Study (women with CHD) and Women's Health Initiative (WHI) studies (some women with but most without CHD)<sup>(123,124)</sup>, and there was an increasing risk of CHD with increasing time since menopause<sup>(125)</sup>. However, in postmenopausal women who were less than 10 years post-menopause, taking oral oestrogen or oestrogen plus progestin reduced risk of CHD by 24%<sup>(125)</sup> and risk of all-cause mortality by 30%<sup>(126)</sup>, although there was still a 74% increased risk of venous embolism with oral HRT<sup>(126)</sup>. A subset of women taking part in the WHI RCT on oral hormone replacement therapy (consuming oestrogen alone or oestrogen plus progestin) had a 10% reduction in DPA and 11% increase in DHA in erythrocyte membrane lipids compared to the control group after 1 year of therapy<sup>(52)</sup>, and similar findings were demonstrated in healthy, early postmenopausal women taking combined oral oestrogen and progestin<sup>(127)</sup>. In addition, a small study reported that women receiving DHA supplementation had lower increases in EPA and higher DHA:EPA ratios if they were taking oral HRT compared to those not on HRT, suggesting reduced retroconversion of DHA to EPA<sup>(128)</sup>. Increasingly, peri- and postmenopausal women are now being prescribed transdermal oestrogen (rather than oral)<sup>(129)</sup>, due to its efficacy in resolving menopausal symptoms and a superior safety profile. Transdermal oestrogen treatments are applied at much lower doses and are metabolised differently to oral treatments, avoiding first-pass hepatic metabolism to pass directly into the bloodstream. Although there is no evidence to suggest that oral and transdermal oestrogen have a differential impact on risk

of CVD<sup>(130,131)</sup>, it is unlikely that transdermal oestrogen reaches the liver in a high enough dose to modulate PPAR activity thus probably having little effect on PUFA metabolism.

Inflammatory burden increases during menopause<sup>(68)</sup> due to the declining impact of oestrogen on optimal function of immune cells<sup>(132)</sup>, skin and mucosal integrity<sup>(133)</sup>, musculoskeletal function<sup>(134)</sup>, moderating cytokine responses to injury/stress<sup>(132)</sup> and resolving inflammatory events<sup>(135)</sup>. The role of EPA and DHA in dampening chronic low-grade inflammation may be especially important during this stage of a woman's life, particularly as the majority of postmenopausal women consume little or no oily fish (Table 1).

The distinct contribution of the range of traditional and sex-specific risk factors to total risk of CVD may differentially modulate the cardioprotective effects of LCn-3 PUFA intake by biological sex, yet dietary guidelines currently do not fully take account of life stages where requirements may be higher in females.

### Conclusions

Many women may have additional female-specific CVD risk factors and greater vulnerabilities to traditional risk factors that arguably put oily fish dietary guidelines as a higher priority for prevention of cardiac death and morbidity compared with men. The existence and magnitude of sex differences in responses to LCn-3 PUFA interventions are poorly understood due to sex comparisons not being built into study designs a priori and lack of consideration of background oestrogen levels. There is an urgent need for more research on cardioprotective dietary interventions across the reproductive lifecycle of women, particularly dietary/supplementary sources of LCn-3 PUFA. In the meantime, while female-specific evidence is lacking, consumption of oily fish or alternative non-fish sources of LCn-3 PUFA should be strongly encouraged as part of dietary recommendations for women.

### Acknowledgements

W.H. would like to thank the Organising Committee of the Nutrition Society Summer Conference 2023 for the speaker invitation.

### Financial support

This work did not receive a specific grant from any funding agency, commercial or not-for-profit sectors.

### Author contributions

WH wrote the manuscript and is responsible for the final content.

### Competing interests

There are no conflicts of interest to declare.

### References

1. Roth GA, Mensah GA, Johnson CO *et al.* (2020) Global burden of cardiovascular diseases and risk factors, 1990–2019. *J Am Coll Cardiol* **76**, 2982–3021.
2. National Institute for Health and Care Excellence (2010) Cardiovascular disease prevention. Public health guideline. [www.nice.org.uk/guidance/ph25](http://www.nice.org.uk/guidance/ph25) (accessed August 2023).
3. Pinho-Gomes AC, Peters SAE, Thomson B *et al.* (2021) Sex differences in prevalence, treatment and control of cardiovascular risk factors in England. *Heart* **107**, 462–467.
4. Mosca L, Hammond G, Mochari-Greenberger H *et al.* (2013) Fifteen-year trends in awareness of heart disease in women. *Circulation* **127**, 1254–1263.
5. Institute for Health Metrics and Evaluation (2020) Global Burden of Disease Collaborative Network Global Burden of Disease Study 2019 (GBD 2019) results. <http://ghdx.healthdata.org/gbd-results-tool> (accessed August 2023).
6. Okoth K, Crowe F, Marshall T *et al.* (2022) Sex-specific temporal trends in the incidence and prevalence of cardiovascular disease in young adults: a population-based study using UK primary care data. *Eur J Preventative Cardiol* **29**, 1387–1395.
7. Vogel B, Acevedo M, Appelman Y *et al.* (2021) The Lancet women and cardiovascular disease commission: reducing the global burden by 2030. *Lancet* **397**, 2385–2438.
8. Wilson PWF, D'Agostino RB, Sullivan L *et al.* (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. *Arch intern medicine* **162**, 1867–1872.
9. Rost S, Freuer D, Peters A *et al.* (2018) New indexes of body fat distribution and sex-specific risk of total and cause-specific mortality: a prospective cohort study. *BMC na na* **18**, 427.
10. Li C, Engström G, Hedblad B *et al.* (2006) Sex differences in the relationships between BMI, WHR and incidence of cardiovascular disease: a population-based cohort study. *Int J Obesity* **30**, 1775–1781.
11. Banack HR, Bea JW, Chen Z *et al.* (2023) Longitudinal patterns of abdominal visceral and subcutaneous adipose tissue, total body composition, and anthropometric measures in postmenopausal women: results from the women's health initiative. *Int J Obesity* **47**, 288–296.
12. Lipsky LM, Strawderman MS & Olson CM (2012) Maternal weight change between 1 and 2 years postpartum: the importance of 1 year weight retention. *Obesity* **20**, 1496–1502.
13. Yusuf S, Hawken S, Ounpuu S *et al.* Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet (London, England)* **364**, 937–952.
14. Ji H, Niiranen TJ, Rader F *et al.* (2021) Sex differences in blood pressure associations with cardiovascular outcomes. *Circulation* **143**, 761–763.
15. Pearson JD, Morrell CH, Brant LJ *et al.* (1997) Age-associated changes in blood pressure in a longitudinal study of healthy men and women. *Journals Gerontology. Ser A, Biol Sci Med Sci* **52**, M177–83.
16. Castelli WP (1992) Epidemiology of triglycerides: a view from Framingham. *Am J Cardiol* **70**, H3–H9.

17. Egeland GM, Igland J, Sulo G *et al.* (2015) Non-fasting triglycerides predict incident acute myocardial infarction among those with favourable HDL-cholesterol: cohort Norway. *Eur J Preventative Cardiol* **22**, 872–881.
18. Wang Y, O'Neil A, Jiao Y *et al.* (2019) Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants. *BMC Med* **17**, 136.
19. de Ritter R, de Jong M, Vos RC *et al.* (2020) Sex differences in the risk of vascular disease associated with diabetes. *Biol Sex Differences* **11**, 1.
20. Peters SAE, Huxley RR & Woodward M (2014) Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia* **57**, 1542–1551.
21. Peters SAE, Huxley RR & Woodward M (2014) Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes. *Lancet* **383**, 1973–1980.
22. Logue J, Walker JJ, Colhoun HM *et al.* (2011) Do men develop type 2 diabetes at lower body mass indices than women?. *Diabetologia* **54**, 3003–3006.
23. Huebschmann AG, Huxley RR, Kohrt WM *et al.* (2019) Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. *Diabetologia* **62**, 1761–1772.
24. Guthold R, Stevens GA, Riley LM *et al.* (2018) Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1·9 million participants. *Lancet Global Health* **6**, e1077–e1086.
25. Lee SN, Yun J-S, Ko S-H *et al.* (2023) Impacts of gender and lifestyle on the association between depressive symptoms and cardiovascular disease risk in the UK Biobank. *Sci Rep* **13**, 10758.
26. Harwood J (2019) Algae: critical sources of very long-chain polyunsaturated fatty acids. *Biomolecules* **9**, 708.
27. Mozaffarian D, Geelen A, Brouwer IA *et al.* (2005) Effect of fish oil on heart rate in humans. *Circulation* **112**, 1945–1952.
28. Xin W, Wei W & Li X-Y (2013) Short-term effects of fish-oil supplementation on heart rate variability in humans: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* **97**, 926–935.
29. Christifano DN, Chollet-Hinton L, Mathis NB *et al.* (2022) DHA supplementation during pregnancy enhances maternal vagally mediated cardiac autonomic control in humans. *J Nutr* **152**, 2708–2715.
30. Song Y-J, Dong P-S, Wang H-L *et al.* (2013) Regulatory functions of docosahexaenoic acid on ion channels in rat ventricular myocytes. *Eur Rev Med Pharmacol Sci* **17**, 2632–2638.
31. Bercea C, Cottrell GS, Tamagnini F *et al.* (2021) Omega-3 polyunsaturated fatty acids and hypertension: a review of vasodilatory mechanisms of docosahexaenoic acid and eicosapentaenoic acid. *Br J Pharmacol* **178**, 860–877.
32. Calder PC (2017) Omega-3 fatty acids and inflammatory processes: from molecules to man. *Biochem Soc Trans* **45**, 1105–1115.
33. Gao L, Cao J, Mao Q *et al.* (2013) Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: a meta-analysis of randomized controlled trials. *Atherosclerosis* **226**, 328–334.
34. Khan S, Minihi A-M, Talmud PJ *et al.* (2002) Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. *J Lipid Res* **43**, 979–985.
35. Tian F, Wang J, Sun H *et al.* (2018) N-3 polyunsaturated fatty acids ameliorate hepatic steatosis via the PPAR- $\alpha$ /CPT-1 $\alpha$  pathway in a mouse model of parenteral nutrition. *Biochem Biophys Res Commun* **501**, 974–981.
36. Kajikawa S, Harada T, Kawashima A *et al.* (2009) Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice. *Prostaglandins, Leukotrienes Essent Fatty Acids* **80**, 229–238.
37. Botolin D, Wang Y, Christian B *et al.* (2006) Docosahexaenoic acid (22:6,n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 26S proteasome-dependent pathways. *J Lipid Res* **47**, 181–192.
38. Wang T, Zhang X, Zhou N *et al.* (2023) Association between omega-3 fatty acid intake and dyslipidemia: a continuous dose–response meta-analysis of randomized controlled trials. *J Am Heart Assoc* **12**, e029512.
39. Scientific Advisory Committee on Nutrition and Committee on Toxicity (2004) *Advice on Fish Consumption: Benefits and Risks*. London: Food Standards Agency and the Department of Health.
40. US Department of Agriculture (USDA) ARSNDL (2023) USDA National Nutrient Database for Standard Reference, Legacy. <https://fdc.nal.usda.gov/fdc-app.html#/food-search> (accessed September 2023).
41. Kralik Z, Kralik G, Košević M *et al.* (2023) Natural multi-enriched eggs with n-3 polyunsaturated fatty acids, selenium, vitamin E, and lutein. *Anim* **13**, 321.
42. Scollan ND, Price EM, Morgan SA *et al.* (2017) Can we improve the nutritional quality of meat?. *Proc Nutr Soc* **76**, 603–618.
43. Nahab F, Pearson K, Frankel MR *et al.* (2016) Dietary fried fish intake increases risk of CVD: the reasons for geographic and racial differences in stroke (REGARDS) study. *Public Health Nutr* **19**, 3327–3336.
44. University of Cambridge, MRC Epidemiology Unit & NatCen Social Research (2021) *National Diet and Nutrition Survey Years 1–11, 2008–2019*, 19th ed. Manchester, England: UK Data Service.
45. Harris WS, Pottala JV, Varvel SA *et al.* (2013) Erythrocyte omega-3 fatty acids increase and linoleic acid decreases with age: observations from 160,000 patients. *Prostaglandins, Leukotrienes Essent Fatty Acids* **88**, 257–263.
46. Burdge GC & Wootton SA (2002) Conversion of  $\alpha$ -linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. *Br J Nutr* **88**, 411–420.
47. Burdge GC, Jones AE & Wootton SA (2002) Eicosapentaenoic and docosapentaenoic acids are the principal products of  $\alpha$ -linolenic acid metabolism in young men. *Br J Nutr* **88**, 355–363.
48. Magnusardottir AR, Steingrimsdottir L, Thorgeirsdottir H *et al.* (2009) Docosahexaenoic acid in red blood cells of women of reproductive age is positively associated with oral contraceptive use and physical activity. *Prostaglandins, Leukotrienes Essent Fatty Acids* **80**, 27–32.
49. Childs CE, Romeu-Nadal M, Burdge GC *et al.* (2008) Gender differences in the n-3 fatty acid content of tissues. *Proc Nutr Soc* **67**, 19–27.
50. Giltay EJ, Gooren LJG, Toorians AWFT *et al.* (2004) Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. *Am J Clin Nutr* **80**, 1167–1174.

51. Abdelmagid SA, Clarke SE, Roke K *et al.* (2015) Ethnicity, sex, FADS genetic variation, and hormonal contraceptive use influence delta-5- and delta-6-desaturase indices and plasma docosahexaenoic acid concentration in young Canadian adults: a cross-sectional study. *Nutr Metab* **12**, 14.
52. Harris WS, Tintle NL, Manson JE *et al.* (2021) Effects of menopausal hormone therapy on erythrocyte n-3 and n-6 PUFA concentrations in the women's health initiative randomized trial. *Am J Clin Nutr* **113**, 1700–1706.
53. Kitson AP, Marks KA, Shaw B *et al.* (2013) Treatment of ovariectomized rats with 17 $\beta$ -estradiol increases hepatic delta-6 desaturase enzyme expression and docosahexaenoic acid levels in hepatic and plasma phospholipids. *Prostaglandins, Leukotrienes Essent Fatty Acids* **89**, 81–88.
54. de Kat AC, Dam V, Onland-Moret NC *et al.* (2017) Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study. *BMC Med* **15**, 2.
55. Staessen J, Ginocchio G, Thijs L *et al.* (1997) Conventional and ambulatory blood pressure and menopause in a prospective population study. *J Hum Hypertens* **11**, 507–514.
56. Derby CA, Crawford SL, Pasternak RC *et al.* (2009) Lipid changes during the menopause transition in relation to age and weight: the study of women's health across the nation. *Am J Epidemiol* **169**, 1352–1361.
57. Wang Q, Ferreira DLS, Nelson SM *et al.* (2018) Metabolic characterization of menopause: cross-sectional and longitudinal evidence. *BMC Med* **16**, 17.
58. Clayton GL, Soares AG, Kilpi F *et al.* (2022) Cardiovascular health in the menopause transition: a longitudinal study of up to 3892 women with up to four repeated measures of risk factors. *BMC medicine* **20**, 299.
59. Ambikairajah A, Walsh E, Tabatabaei-Jafari H *et al.* (2019) Fat mass changes during menopause: a meta-analysis. *Am J Obstetrics Gynecology* **221**, 393–409.e50.
60. Iwamoto E, Sakamoto R, Tsuchida W *et al.* (2021) Effects of menstrual cycle and menopause on internal carotid artery shear-mediated dilation in women. *Am J Physiology-Heart Circulatory Physiol* **320**, H679–H689.
61. Innes JK & Calder PC (2020) Marine omega-3 (N-3) fatty acids for cardiovascular health: an update for 2020. *Int J Mol Sci* **21**, 1362.
62. Hu FB (2002) Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. *JAMA* **287**, 1815.
63. Zhang B, Xiong K, Cai J *et al.* (2020) Fish consumption and coronary heart disease: a meta-analysis. *Nutrients* **12**, 2278.
64. Abdelhamid AS, Brown TJ, Brainard JS *et al.* (2020) Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev* **2020**, CD003177.
65. Wei MY & Jacobson TA (2011) Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. *Curr Atherosclerosis Rep* **13**, 474–483.
66. Caslake MJ, Miles EA, Kofler BM *et al.* (2008) Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. *Am J Clin Nutr* **88**, 618–629.
67. Sanders TAB, Hall WL, Maniou Z *et al.* (2011) Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. *Am J Clin Nutr* **94**, 973–980.
68. Bermingham KM, Linenberg I, Hall WL *et al.* (2022) Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The zoe predict study. *EBioMedicine* **85**, 104303.
69. Slivkoff-Clark KM, James AP & Mamo JCL (2012) The chronic effects of fish oil with exercise on postprandial lipaemia and chylomicron homeostasis in insulin resistant visceraally obese men. *Nutr Metab* **9**, 9.
70. Griffin MD, Sanders TAB, Davies IG *et al.* (2006) Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45–70 y: the optilip study. *Am J Clin Nutr* **84**, 1290–1298.
71. Chan DC, Pang J, Barrett PHR *et al.* (2016)  $\omega$ -3 fatty acid ethyl esters diminish postprandial lipemia in familial hypercholesterolemia. *J Clin Endocrinol Metab* **101**, 3732–3739.
72. Slivkoff-Clark KM, James AP & Mamo JCL (2012) The chronic effects of fish oil with exercise on postprandial lipaemia and chylomicron homeostasis in insulin resistant visceraally obese men. *Nutr Metab* **9**, 9.
73. Jiménez-Gómez Y, Marin C, Peérez-Martínez P *et al.* (2010) A low-fat, high-complex carbohydrate diet supplemented with long-chain (n-3) fatty acids alters the postprandial lipoprotein profile in patients with metabolic syndrome. *J Nutr* **140**, 1595–1601.
74. Harris WS, Connor WE, Alam N *et al.* (1988) Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. *J Lipid Res* **29**, 1451–1460.
75. Yokoyama M, Origasa H, Matsuzaki M *et al.* (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet* **369**, 1090–1098.
76. GISSI-HF & investigators (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* **372**, 1223–1230.
77. Marchioli R, Barzi F, Bomba E *et al.* (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. *Circulation* **105**, 1897–1903.
78. Burr ML, Gilbert JF, Holliday RM *et al.* (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). *Lancet* **334**, 757–761.
79. Kalstad AA, Myhre PL, Laake K *et al.* (2021) Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction. *Circulation* **143**, 528–539.
80. Risk and Prevention Study Collaborative Group, Roncaglioni M, Tombesi M *et al.* (2013) n-3 fatty acids in patients with multiple cardiovascular risk factors. *N Engl J Med* **368**, 1800–1808.
81. ORIGIN Trial Investigators, Bosch J, Gerstein H *et al.* (2012) n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *N Engl J Med* **367**, 309–318.
82. Kromhout D, Giltay EJ & Geleijnse JM (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. *N Engl J Med* **363**, 2015–2026.
83. Galan P, Kesse-Guyot E, Czernichow S *et al.* (2010) Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. *BMJ* **341**, c6273–c6273.
84. Rauch B, Schiele R, Schneider S *et al.* (2010) OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. *Circulation* **122**, 2152–2159.



85. Rice HB, Bernasconi A, Maki KC *et al.* (2016) Conducting omega-3 clinical trials with cardiovascular outcomes: proceedings of a workshop held at ISSFAL 2014. *Prostaglandins, Leukotrienes Essent Fatty Acids* **107**, 30–42.
86. Balk EM, Adam GP, Langberg V *et al.* (2016) Omega-3 fatty acids and cardiovascular disease: an updated systematic. *Rev* **223**, 1–1252.
87. Aung T, Halsey J, Kromhout D *et al.* (2018) Associations of omega-3 fatty acid supplement use with cardiovascular disease risks. *JAMA Cardiol* **3**, 225.
88. Rizos EC, Ntzani EE, Bika E *et al.* (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events. *JAMA* **308**, 1024.
89. Kwak S, Myung S-K, Lee Y *et al.* (2012) Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease. *Arch Internal Med* **172**, 686.
90. Hu Y, Hu FB & Manson JE (2019) Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants. *J Am Heart Assoc* **8**, e013543.
91. Khan SU, Lone AN, Khan MS *et al.* (2021) Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. *EClinicalMedicine* **38**, 100997.
92. Manson JE, Cook NR, Lee I-M *et al.* (2019) Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. *N Engl J Med* **380**, 23–32.
93. Bhatt DL, Steg PG, Miller M *et al.* (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med* **380**, 11–22.
94. Nicholls SJ, Lincoff AM, Garcia M *et al.* (2020) Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk. *JAMA* **324**, 2268.
95. The ASCEND Study Collaborative Group (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. *N Engl J Med* **379**, 1540–1550.
96. Doi T, Langsted A & Nordestgaard BG (2021) A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. *Eur Heart J* **42**, 4807–4817.
97. Olshansky B, Chung MK, Budoff MJ *et al.* (2020) Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. *Eur Heart J Supplements* **22**, J34–J48.
98. Miller M, Tokgozoglu L, Parhofer KG *et al.* (2022) Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. *Expert Rev Cardiovasc Ther* **20**, 609–625.
99. Jacob L, Greiner R-A, Luedde M *et al.* (2021) Prevalence of and factors associated with the prescription of fibrates among patients receiving lipid-lowering drugs in Germany. *J Cardiovasc Pharmacol* **78**, 885–890.
100. Zhao M, Woodward M, Vaartjes I *et al.* (2020) Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis. *J Am Heart Assoc* **9**, e014742.
101. Wilkinson C, Bebb O, Dondo TB *et al.* (2019) Sex differences in quality indicator attainment for myocardial infarction: a nationwide cohort study. *Heart* **105**, 516–523.
102. NACR Writing Group (2019) *The National Audit of Cardiac Rehabilitation Quality and Outcomes Report 2019*. Hampstead Road, London: British Heart Foundation.
103. Li S, Fonarow GC, Mukamal K *et al.* (2018) Sex and racial disparities in cardiac rehabilitation referral at hospital discharge and gaps in long-term mortality. *J Am Heart Assoc* **7**, e008088.
104. McGill HC, McMahan CA, Herderick EE *et al.* (2000) Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. *Arteriosclerosis, Thrombosis, Vasc Biol* **20**, 836–845.
105. Okoth K, Smith WP, Thomas GN *et al.* (2023) The association between menstrual cycle characteristics and cardiometabolic outcomes in later life: a retrospective matched cohort study of 704,743 women from the UK. *BMC Med* **21**, 104.
106. Solomon CG, Hu FB, Dunaif A *et al.* (2002) Menstrual cycle irregularity and risk for future cardiovascular disease. *J Clin Endocrinol Metab* **87**, 2013–2017.
107. Bertone-Johnson ER, Whitcomb BW, Rich-Edwards JW *et al.* (2015) Premenstrual syndrome and subsequent risk of hypertension in a prospective study. *Am J Epidemiol* **182**, 1000–1009.
108. Chung H-F, Ferreira I & Mishra GD (2021) The association between menstrual symptoms and hypertension among young women: a prospective longitudinal study. *Maturitas* **143**, 17–24.
109. Yeh C-H, Muo C-H, Sung F-C *et al.* (2022) Risk of ischemic heart disease associated with primary dysmenorrhea: a population-based retrospective cohort study. *J Pers Med* **12**, 1610.
110. Mohammadi MM, Dehghan Nayeri N, Mashhadi M *et al.* (2022) Effect of omega-3 fatty acids on premenstrual syndrome: a systematic review and meta-analysis. *J Obstetrics Gynaecology Res* **48**, 1293–1305.
111. Snipe RMJ, Brelis B, Kappas C *et al.* (2023) Omega-3 long chain polyunsaturated fatty acids as a potential treatment for reducing dysmenorrhoea pain: systematic literature review and meta-analysis. *Nutr Diet* **81**, 94–106.
112. Zhao H, Zhang J, Cheng X *et al.* (2023) Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. *J Ovarian Res* **16**, 9.
113. Ollila M-ME, Piltonen T, Puukka K *et al.* (2016) Weight gain and dyslipidemia in early adulthood associate with polycystic ovary syndrome: prospective cohort study. *J Clin Endocrinol Metab* **101**, 739–747.
114. Ollila M-ME, Kaikkonen K, Järvelin M-R *et al.* (2019) Self-reported polycystic ovary syndrome is associated with hypertension: a northern finland birth cohort 1966 study. *J Clin Endocrinol Metab* **104**, 1221–1231.
115. Xia Y, Wang Y, Cui M *et al.* (2021) Efficacy of omega-3 fatty acid supplementation on cardiovascular risk factors in patients with polycystic ovary syndrome: a systematic review and meta-analysis. *Ann Palliative Med* **10**, 6425–6437.
116. Crump C, Sundquist J, McLaughlin MA *et al.* (2023) Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study. *BMJ* **380**, e072112.
117. Parikh NI, Gonzalez JM, Anderson CAM *et al.* (2021) Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American heart association. *Circulation* **143**, e902–e916.
118. Wu P, Gulati M, Kwok CS *et al.* (2018) Preterm delivery and future risk of maternal cardiovascular disease: a systematic review and meta-analysis. *J Am Heart Assoc* **7**, e007809.

119. Wu P, Haththotuwa R, Kwok CS *et al.* (2017) Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. *Circulation: Cardiovascular Quality and Outcomes* **10**, e003497.
120. Li J, Song C, Li C *et al.* (2018) Increased risk of cardiovascular disease in women with prior gestational diabetes: a systematic review and meta-analysis. *Diabetes Res Clin Pract* **140**, 324–338.
121. Mackay VA, Huda SS, Stewart FM *et al.* (2012) Preeclampsia is associated with compromised maternal synthesis of long-chain polyunsaturated fatty acids, leading to offspring deficiency. *Hypertens* **60**, 1078–1085.
122. Middleton P, Gomersall JC, Gould JF *et al.* (2018) Omega-3 fatty acid addition during pregnancy. *Cochrane Database Syst Rev* **11**, CD003402.
123. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. *JAMA: The Journal of the American Medical Association* **288**, 321–333.
124. Hulley S (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA* **280**, 605.
125. Rossouw JE, Prentice RL, Manson JE *et al.* (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA* **297**, 1465–1477.
126. Boardman HM, Hartley L, Eisinga A *et al.* (2015) Hormone therapy for preventing cardiovascular disease in post-menopausal women. *Cochrane Database Syst Rev* **2015**, CD002229.
127. Giltay E, Duschek E, Katan M *et al.* (2004) Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women. *J Endocrinol* **182**, 399–408.
128. Stark KD & Holub BJ (2004) Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. *Am J Clin Nutr* **79**, 765–773.
129. Alsugeir D, Wei L, Adesuyan M *et al.* (2022) Hormone replacement therapy prescribing in menopausal women in the UK: a descriptive study. *BJGP Open* **6**, BJGPO.2022.0126.
130. Goldštajn MŠ, Mikuš M, Ferrari FA *et al.* (2022) Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. *Arch Gynecology Obstetrics* **307**, 1727–1745.
131. de Vries CS, Bromley SE & Farmer RDT (2006) Myocardial infarction risk and hormone replacement: differences between products. *Maturitas* **53**, 343–350.
132. Gameiro CM, Romão F & Castelo-Branco C (2010) Menopause and aging: changes in the immune system—a review. *Maturitas* **67**, 316–320.
133. Rahn DD, Good MM, Roshanravan SM *et al.* (2014) Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. *J Clin Endocrinol Metab* **99**, 3728–3736.
134. Watt FE (2018) Musculoskeletal pain and menopause. *Post Reprod Health* **24**, 34–43.
135. Villa A, Rizzi N, Vegeto E *et al.* (2015) Estrogen accelerates the resolution of inflammation in macrophagic cells. *Sci Rep* **5**, 15224.
136. Bonds DE, Harrington M, Worrall BB *et al.* (2014) Effect of long-chain  $\omega$ -3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. *JAMA Intern Med* **174**, 763–771.